Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...
Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II
Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...
Zacks Research Has Weak Estimate for DNLI FY2024 Earnings
Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...
Q1 Earnings Forecast for TSE:CP Issued By Raymond James
Raymond James analyst S. Hansen now anticipates that the company will post earnings per share of $1.15 for the quarter, down from their prior estimate of $1.19. The consensus estimate for Canadian ...